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Background: Autophagy is a self-catabolic mechanism that degrades unnecessary cellular components through
lysosomal enzymes. Beclin-1, an autophagy-related protein, establishes the first connection between autophagy and
tumorigenesis. The purpose of this study is to assess the Beclin-1 expression pattern and to determine its
prognostic significance in patients with malignant canine mammary tumor (CMT).
Results: We examined Beclin-1 expression in 70 cases of malignant CMTs by immunohistochemistry. Cytoplasmic
Beclin-1 expression was significantly weaker in cancer cells than in nearby normal mammary glands (p < 0.001). Low
cytoplasmic expression (57.14%) was associated with older age, lower degree of tubular formation, increased
mitotic activity, higher histologic grade, and extensive necrosis. Low nuclear expression (40%) was connected with
older age, lower degree of tubular formation, extensive necrosis, and negative for Her2/neu overexpression.
Univariate survival analysis showed that Beclin-1 cytoplasmic expression was a poor prognostic factor for overall
survival rate (p < 0.001). Multivariate survival analysis demonstrated that Beclin-1 cytoplasmic expression is an
independent prognostic factor (p = 0.016).
Conclusions: Loss of Beclin-1 is associated with aggressive clinicopathologic features and poor overall survival.
The results suggest that Beclin-1 plays an important role in tumor progression of malignant CMTs.
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Canine mammary tumors (CMTs) are the most common
neoplasms in intact female dogs. Approximately half of
CMTs are malignant. Histologically, the majority of
malignant CMTs are carcinomas, whereas approximately
10% are sarcomas. The spontaneously occurring malignant
CMTs share many clinicopathologic and molecular char-
acteristics with human breast cancers. The comparative
analysis of human and dog genomes demonstrates the
similarity of orthologous genes between the 2 species
[1,2]. Therefore, malignant CMTs can be used as a suit-
able animal model for oncogenesis research and treatment
protocols.
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reproduction in any medium, provided the ortypes of programmed cell death, apoptosis and autophagy,
have been subjects of increasing attention to scientists.
Apoptosis involves the activation of catabolic enzymes in
the signaling transduction pathway that leads to self-
destruction. The term “autophagy” was first introduced in
1963 by de Duve, the discoverer of lysosomes [3]. Autoph-
agy is a self-catabolic process that involves the degradation
of intracellular structures and organelles by lysosomal
enzymes [4]. Autophagy is essential for development,
homeostasis, and survival, especially for stress adaption in
an energy-deficient environment. It is also closely related to
many pathologic processes, such as infections, metabolic
disorders, neurodegeneration, and tumorigenesis [5].
Autophagy is regulated by a group of evolutionarily con-
served genes, which were first discovered in yeast [6]. To
date, more than 30 autophagy-related genes have been
identified. The BECN1 gene is the mammalian orthologue
of the yeast apg6/vps30, and was the first gene to establish
a connection between autophagy and tumorigenesis
[7]. Two research groups have shown that BECN1
heterozygous-deficient mice have a higher frequencyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mice died early in embryogenesis because of defects
in proamniotic canal closure [8,9]. They concluded
that BECN1 is a haplo-insufficient tumor suppressor
gene. The Beclin-1 protein, which is encoded by the
BECN1 gene, is involved in the signaling pathway of
autophagy and is required for the nucleation of the
phagophore and maturation of the autolysosome.
Beclin-1 expression can indicate autophagic activity in cells.
Beclin-1 expression and its association with clinicopatho-
logic features have not been described in canine cancer.
The aims of the study were to compare Beclin-1 expression
patterns in normal mammary glands and malignant CMTs,
to investigate the clinicopathologic significance of Beclin-1
expression, and to evaluate its impact on clinical outcomes.
Results
Patient characteristics
This study comprised 70 cases of malignant CMTs,
including 54 simple carcinomas, 11 complex carcinomas,
and 5 sarcomas. The mean age of 69 dogs at the time of
surgery was 11.3 ± 2.7 years (ranging from 4 to 18 years).
The age of the remaining dog was unknown. In total, 16
of 70 (22.9%) dogs received ovario-hysterectomy prior to
the surgical removal of tumors. The mean maximum
tumor size was 4.3 ± 3.1 cm (ranging from 0.4 to 15.0 cm).
The other clinicopathologic features, including tumor loca-
tion, tubular formation, nuclear pleomorphism, mitotic
count, histologic grade, lymphovascular invasion, necro-
sis, expressions of estrogen receptor and Her2, were
summarized in Table 1.
Comparison of Beclin-1 expression in normal mammary
glands and cancer cells
The normal mammary glands near the cancer cells showed
weak or moderate cytoplasmic reactivity and variable
nuclear expression of Beclin-1 (Figure 1). The cancer cells
displayed negative, weak, or moderate cytoplasmic staining,
and ranged from non-reactivity to strong positivity of
nuclear expression (Figure 2). The cytoplasmic Q score of
normal mammary glands was significantly higher than that
of cancer cells (p < 0.001). The difference of nuclear Q
score between normal glands and cancer cells was
not statistically significant (p = 0.130) (Figure 3).
Association of Beclin-1 expression in cancer cells and
clinicopathologic characteristics
The associations between Beclin-1 expression patterns
and clinicopathologic variables are shown in Table 1.
The median value of the Q score of cytoplasmic Beclin-1
expression in malignant CMTs was 60. Using the median
value as a cutoff point, 40 cases (57.14%) were classified
as low cytoplasmic expression, whereas 30 cases
(42.86%) were classified as high cytoplasmic expression.Low cytoplasmic expression (Q score ≦60) of Beclin-1
was associated with older age, lower degree of tubular
formation, increased mitotic activity, higher histologic
grade, and extensive necrosis. The median value of the
nuclear Q score in malignant CMTs was 10. In total, 28
cases (40%) were sub-grouped into low nuclear expression,
and 42 cases (60%) were sub-grouped into high nuclear
expression. Low nuclear expression (Q score ≦10) of
Beclin-1 was linked to older age, lower degree of tubular
formation, extensive necrosis, and negative for Her2/neu
overexpression. Beclin-1 cytoplasmic expression was linked
significantly with nuclear expression (p = 0.003) (Table 2).
Survival analysis
The mean follow-up time was 21 ± 18.72 months.
Univariate survival analysis using the Kaplan-Meir
method revealed that age, tumor size, tubular formation,
nuclear pleomorphism, mitotic count, histologic grade,
lymphovascular invasion, necrosis, and Beclin-1 cyto-
plasmic expression were significant prognostic factors
for overall survival (Table 3). Figure 4 shows the Kaplan-
Meier curves of cumulative overall survival probability
in relation to the Beclin-1 expression of cancer cells.
Patients with low cytoplasmic expression showed poorer
overall survival rate (p < 0.001). The difference of overall
survival rate between high and low nuclear expressions
was not statistically significant (p = 0.074). Multivariate
survival analysis using the Cox proportional hazard
regression method revealed that tumor size, tubular
formation, and Beclin-1 cytoplasmic expression were inde-
pendent prognostic factors for malignant CMTs (Table 4).
Discussion
Autophagy, an essential catabolic mechanism, is also
involved in tumor initiation and progression. Recent
studies have revealed that the expression of Beclin-1 is
decreased in various human cancer types, such as breast
[10], cervical [11], esophageal [12], lung cancers [13,14],
hepatocellular carcinoma [15], and cutaneous melanoma
[16]. However, Beclin-1 expression was reported to be
increased in human colon, gastric, and pancreatic
cancers, in contrast to their normal counterparts [17,18].
The mechanism of aberrance of Beclin-1 expression in
different types of cancers is largely unknown. These vari-
able results imply that autophagic activity is specific in
different organs and histologic types. They also indicate
that autophagy may either induce or inhibit tumor cell
survival. In this study, we compared the Beclin-1 expression
in malignant CMTs and surrounding normal mammary
glands. Cytoplasmic expression of cancer cells was signifi-
cantly lower than that of normal mammary glands.
Decreased expression of Beclin-1 was associated with some
aggressive histologic features. These findings were similar
to those of human breast cancer [7,10]. Malignant CMT
Table 1 Association of Beclin-1 expression pattern and clinicopathologic variables in 70 cases of malignant CMTs
Beclin-1 cytoplasmic expression p value Beclin-1 nuclear expression p value
Variable No. of cases Low High Low High
Agea
≦ 11 years 36 15 (38.5%) 21 (70.0%) 0.009* 10 (37.0%) 26 (61.9%) 0.044*
> 11 years 33 24 (61.5%) 9 (30.0%) 17 (63.0%) 16 (38.1%)
Location of affected gland
Cranial gland 24 14 (35.0%) 10 (33.3%) 0.953 9 (32.1%) 15 (35.7%) 0.890
Caudal gland 42 24 (60.0%) 18 (60.0%) 17 (60.7%) 25 (59.5%)
Both 4 2 (5.0%) 2 (6.7%) 2 (7.1%) 2 (4.8%)
Tumor size
≦ 3 cm 27 13 (32.5%) 14 (46.7%) 0.228 9 (32.1%) 18 (42.9%) 0.367
> 3 cm 43 27 (67.5%) 16 (53.3%) 19 (67.9%) 24 (57.1%)
Histologic classification
Simple carcinoma 54 30 (75.0%) 24 (80.0%) 0.877 23 (82.1%) 31 (73.8%) 0.640
Complex carcinoma 11 7 (17.5%) 4 (13.3%) 3 (10.7%) 8 (19.0%)
Sarcoma 5 3 (7.5%) 2 (6.7%) 2 (7.1%) 3 (7.1%)
Tubular formation
> 10% of the tumor 45 19 (47.5%) 26 (86.7%) 0.001* 14 (50.0%) 31 (73.8%) 0.042*
≦ 10% of the tumor 25 21 (52.5%) 4 (13.3%) 14 (60.0%) 11 (26.2%)
Nuclear pleomorphism
Mild to moderate 46 17 (42.5%) 19 (63.3%) 0.084 12 (42.9%) 24 (57.1%) 0.241
Marked 34 23 (57.5%) 11 (36.7%) 16 (57.1%) 18 (42.9%)
Mitotic count
≦10/10 HPFs 52 25 (62.5%) 27 (90.0%) 0.009* 18 (64.3%) 34 (81.0%) 0.118
>10/10 HPFs 18 15 (37.5%) 3 (10%) 10 (35.7%) 8 (19.0%)
Histologic grade
Grades 1 and 2 56 27 (67.5%) 29 (96.7%) 0.003* 18 (64.3%) 38 (90.5%) 0.007*
Grade 3 14 13 (32.5%) 1 (3.3%) 10 (35.7%) 4 (9.5%)
Lymphovascular invasion
Absent 51 26 (65.0%) 25 (83.3%) 0.088 19 (67.9%) 32 (76.2%) 0.442
Present 19 14 (35.0%) 5 (16.7%) 9 (32.1%) 10 (23.8%)
Necrosis
Limited/no necrosis 41 17 (42.5%) 24 (80%) 0.002* 12 (42.9%) 29 (69.0%) 0.029*
Extensive necrosis 29 23 (57.5%) 6 (20%) 16 (57.1%) 13 (31.0%)
Estrogen receptor
Negative 25 16 (40%) 9 (30%) 0.388 9 (32.1%) 16 (38.1%) 0.611
Positive 45 24 (60%) 21 (70%) 19 (67.9%) 26 (61.9%)
Her2 overexpression
Negative 51 29 (72.5%) 22 (73.3%) 0.938 24 (85.7%) 27 (64.3%) 0.048*
Positive 19 11 (27.5%) 8 (26.7%) 4 (14.3%) 15 (35.7%)
HPF, High power field.
aThe age of one case is unknown.
*p < 0.05.
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Figure 1 Beclin-1 expression in normal mammary glands of
dogs. The normal mammary glands show diffuse moderate
cytoplasmic expression and scattered nuclear expression.
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tic features to human breast cancer. Our results imply that
the autophagic activities in canine and human mammary
glands may also be coincidental. Further comparative
studies of autophagy may be beneficial to both human
beings and dogs.
The subcellular localization of Beclin-1 was mainly
reported at the cytoplasm and/or membrane, and theFigure 2 Beclin-1 expression patterns in malignant CMTs. (A) High cyt
and low nuclear expression pattern. (C) Low cytoplasmic and high nuclear
expression pattern.nuclear expression pattern was also documented [19,20].
The leucine-rich nuclear export signal of Beclin-1 is essen-
tial for autophagic growth control and tumor suppression
[21]. Our study disclosed that nuclear expression is associ-
ated with cytoplasmic expression. Lower nuclear expression
is also related to unfavorable clinicopathologic features.
The relationship between the expression pattern of
Beclin-1 and the prognosis was controversial in studies of
human cancer. Loss of Beclin-1 was linked to poorer sur-
vival rate in stage III colon cancer [19], esophageal squa-
mous cell carcinoma [12], hepatocellular carcinoma [15],
intrahepatic cholangiocarcinoma [22], pancreatic ductal
adenocarcinoma [18], chondrosarcoma [23], and several
types of lymphoma [24-26]. High Beclin-1 expression was
connected to poor prognosis in endometrial adenocarcin-
oma [27] and nasopharyngeal carcinoma in humans [28].
Koukourakis et al. found that extensive overexpression
and underexpression of Beclin-1 was associated with
poor overall survival in human patients with colon
cancer [20]. They noted that the nuclear expression
of Beclin-1 was not related to the prognosis. These
results indicate that Beclin-1 may either induce or
inhibit tumor cell survival. Our results support the
hypothesis that Beclin-1 functions as a tumor suppressor
protein in malignant CMTs. The mechanisms by which
autophagy suppresses and promotes carcinogenesis are
not yet completely understood.oplasmic and high nuclear expression pattern. (B) High cytoplasmic
expression pattern. (D) Low cytoplasmic and low nuclear
Figure 3 Comparison of Q scores of Beclin-1 in normal
mammary glands and malignant CMTs. A. Cytoplasmic
expression in normal mammary glands. B. Cytoplasmic expression in
malignant CMTs. C. Nuclear expression in normal mammary glands.
D. Nuclear expression in malignant CMTs. The middle lines of boxes
show the median value, whereas top and bottom lines of boxes
represent interquartile range. The ends of whiskers represent 10th
and 90th percentiles. The outliers are indicated by open circles.
Table 3 Univariate analysis of clinicopathologic variables
for ovarall survival rate
Variables p value
Age (> 11 years vs. ≦ 11 years) 0.001*
Tumor size (> 3 cm vs. ≦ 3 cm) 0.042*
Tubular formation (> 10% vs. ≦ 10%) <0.001*
Nuclear pleomorphism (high vs. low) 0.044*
Mitotic count (> 11 vs. ≦ 10/10 HPFs) 0.005*
Histologic grade (3 vs. 2 and 1) <0.001*
Lymphovascular invasion (yes vs. no) <0.001*
Necrosis (extensive vs. limited/no) 0.004*
Estrogen receptor (negative vs. positive) 0.180
Her2/neu overexpression (positive vs. negative) 0.348
Beclin-1 cytoplasmic expression (low vs. high) <0.001*
Beclin-1 nuclear expression (low vs. high) 0.074
* p < 0.05.
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are clinically effective in cancer treatment [29-32]. The
autophagic tumor stroma model of cancer proposed by
Martinez-Outschoorn et al. attempted to resolve the
paradox [33]. In this model, cancer cells use oxidative
stress to induce autophagy in the tumor environment,
whereas the autophagic tumor stromal cells produce
recycled nutrients to promote the growth of cancer cells
[34]. Sanchez et al. discovered that the mesenchymal
stem cell-derived stromal cells in human breast cancer
showed upregulation of Beclin-1 and other autophagic
markers [35]. However, this model may not explain the
upregulation of autophagy-related proteins in some
human cancer cells. Our study and other previous
researches did not find a specific immunohistochemi-
cal staining pattern of Beclin-1 in cancer-associated
stromal cells. Moreover, the Beclin-1 independent
autophagic process may also be considered. More
proteomic-based studies should be performed to clarify
the functions of autophagy-related proteins in cancer and
cancer-associated stromal cells.Table 2 Association of nuclear expression and
cytoplasmic expression of Beclin-1 in 70 cases of
malignant CMTs
Nuclear expression
Low High p value
Cytoplasmic expression Low 22 (31.43%) 18 (25.71%) 0.003*
High 6 (8.57%) 24 (34.29%)
* p < 0.05.Conclusions
We analyzed the Beclin-1 expression pattern in normal
mammary glands and malignant CMTs. We found that
the loss of Beclin-1 expression is associated with aggres-
sive clinicohistologic features and poor overall survival.
Our results suggest that Beclin-1 plays a significant role
in tumor progression and can be a potential therapeutic
target for malignant CMTs in the future.
Methods
Patients and tissue samples
Formalin-fixed, paraffin-embedded tissue samples from
70 female dogs with primary malignant CMTs were ana-
lyzed in this study. The 70 dogs included 21 mongrels,
19 Maltese, 7 Shih-Tzus, 6 poodles, 4 Cocker spaniels, 4
Schnauzers, 4 Yorkshire terriers, 2 Labrador retrievers, 1
French spaniel, 1 Pomeranian, and 1 spitz. All of these
specimens were surgically resected at National Taiwan
University Veterinary Hospital from 2005 to 2011.
Patients who received chemotherapy before or after
surgery were excluded from this study. All cases were
pathologically diagnosed with primary malignant CMTs
at the School of Veterinary Medicine, National Taiwan
University. Information such as age, breed, status of
ovario-hysterectomy, and tumor size of patients was
obtained from medical records. Follow-up data were
obtained from medical records and by telephone contact
with the dog owners. Overall survival was defined as the
time between surgery and death.
Pathologic examination
Routine hematoxylin and eosin (HE) staining was
performed for histologic assessment. The histologic type
was assessed according to the diagnostic criteria of the
World Health Organization Histological Classification of
Figure 4 Kaplan-Meier curves of overall survival rate in 70 cases of malignant CMTs. (A) Curves for patients with low and high cytoplasmic
Beclin-1 expressions. (B) Curves for patients with low and high nuclear Beclin-1 expressions.
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Table 4 Multivariate Cox proportional hazard analysis of







Age (> 11 years vs. ≦ 11 years) 1.460 0.683 - 3.124 0.329
Tumor size (> 3 cm vs. ≦ 3 cm) 3.038 1.298 - 7.108 0.010*
Tubular formation
(> 10% vs. ≦ 10%)
0.364 0.167 - 0.794 0.011*
Nuclear pleomorphism
(high vs. low)
1.001 0.445 - 2.253 0.997
Mitotic count (> 11 vs.
≦ 10/10 HPFs)
0.881 0.166 - 4.676 0.882
Histologic grade (3 vs. 2 and 1) 0.627 0.088 - 4.486 0.642
Lymphovascular
invasion (yes vs. no)
2.286 0.887 - 5.887 0.087
Necrosis (extensive
vs. limited/no)
0.977 0.473 - 2.019 0.951
Estrogen receptor
(negative vs. positive)
0.499 0.232 - 1.076 0.076
Her2/neu overexpression
(positive vs. negative)
2.433 0.950 - 6.234 0.064
Beclin-1 cytoplasmic expression
(low vs. high)
2.752 1.211 - 6.256 0.016*
Beclin-1 nuclear expression
(low vs. high)
1.471 0.667 - 3.243 0.339
* p < 0.05.
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were graded based on Nottingham Modification of the
Bloom-Richardson system on HE-stained sections [37,38].
The grading system combined 3 histopathologic features:
tubular formation, nuclear pleomorphism, and mitotic
counts. Each feature was scored 1 to 3 points. The histo-
logic grade was according to the final scores as follows: 3,
4, or 5 points as grade I (well differentiated); 6 or 7 points
as grade II (moderately differentiated); and 8 or 9 points as
grade III (poorly differentiated). Necrotic areas of more
than 10% of the tissue section were regarded as “extensive,”
whereas the remaining cases were recorded as “limited/no”
necrosis. The presence of cancer cells within vascular
channels of the primary tumor was detected in HE–stained
sections.
Immunohistochemical staining
Tissue blocks containing representative cancer areas
with surrounding normal breast tissue were selected from
every case. Immunohistochemical staining was performed
on 4-μm-thick tissue sections using the Leica Bond-Max
autostainer (Leica microsystem) according to the manufac-
turer’s instructions with minor modifications. Sections were
deparaffinized by the Bond Dewax Solution (Leica
Microsystems). Heat-induced antigen retrieval was achieved
using the Bond Epitope Retrieval Solution 2 (LeicaMicrosystems) for 20 min at 100°C. Endogenous peroxidase
activity was blocked by incubation of tissue with the
Novocastra Peroxidase Block for 5 min. The slides were
then incubated for 30 min at room temperature with a pri-
mary rabbit polyclonal antibody against Beclin-1 (1: 400,
Abcam, UK), estrogen receptor (1:50, clone 6 F11,
Novocastra, UK), and Her2 (1:50, clone CB11, Novocastra,
UK). Diaminobenzidine-tetrahydrochloride (DAB) was used
as the substrate to detect antigen-antibody binding.
Sections were counterstained with hematoxylin.
Immunohistochemical evaluation
For Beclin-1, the intensity, percentage, and sub-localization
of immunohistochemical stains in cancer cells and cancer-
adjacent normal mammary glands of each case were
recorded. The normal canine mammary ductal epithelium
from dogs without mammary neoplasia was used as posi-
tive control, and staining with omission of primary antibody
was performed as negative control. The intensity and
percentage of positively stained cells were counted at 10
high-powered fields (400 ×). The intensity of staining was
recorded as 0, 1, 2, and 3 standing for negative, weak, mod-
erate and strong staining, respectively. The percentage of
positive cells was scored from 0% to 100%. The results of
cytoplasmic and nuclear Beclin-1 expressions were scored
by quick score (Q), which is obtained by multiplying
the percentage of positive cells (P) by the intensity
(I) (Q = P × I; maximum= 300) [39]. The median value of
the Q score in cancer cells was used as a cutoff point, and
the cases were sub-grouped into “low expression” and
“high expression”.
The Her2 expression was scored according to the
American Society of Clinical Oncology/College of
American Pathologists guidelines (0 = no staining or
membrane staining in fewer than 10% of tumor cells;
1 + = faint, barely perceptible membrane staining in
more than 10% of tumor cells; 2 + = weak to moderate
complete membrane staining observed in more than
10% of tumor cells or strong complete membrane
staining in less than 30% of tumor cells; 3 + = strong
and complete membrane staining in more than 30% tumor
cells) [40]. In this study, Her2 positive was defined as a
score of 3+, whereas the rest were regarded as negative.
For estrogen receptor, nuclear staining more than 10% of
cancer cells were classified as positive, while the others
were classified as negative.
Immunohistochemical staining was evaluated by two
pathologists independently without knowledge of clin-
ical outcomes of the patients. Conflicting results were
resolved at multi-headed microscope.
Statistical analysis
The Wilcoxon signed-rank test was used to analyze
Beclin-1 expression in paired normal mammary glands
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evaluate the association of Beclin-1 expression with
clinicopathologic features of malignant CMTs. Curves
for overall survival were drawn using the Kaplan-Meier
method, and the differences of survival rate were
compared using the log-rank test for univariate survival
analysis. The Cox proportion hazard regression model
was used for multivariate survival analysis of prognostic
factors. A p value of less than 0.05 was considered statisti-
cally significant. The statistical analysis was performed by
SPSS 19.0 software in Windows.
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